期刊
BRITISH JOURNAL OF CANCER
卷 126, 期 8, 页码 1157-1167出版社
SPRINGERNATURE
DOI: 10.1038/s41416-021-01650-0
关键词
-
类别
资金
- Breast Cancer Research Trust [272214]
- NIHR Manchester Biomedical Research Centre [IS-BRC-1215-20007]
The study found that intermittent energy restriction (IER) during chemotherapy shows potential for weight control and reducing toxicity, with significant reductions in weight and body fat compared to continuous energy restriction (CER) in adjusted secondary analyses. Additionally, there was a trend towards fewer grade 3/4 toxicities with IER during cycles 4-6 of primarily taxane therapy. Further research in larger trials is needed to confirm the efficacy of IER in this context.
Background Excess adiposity at diagnosis and weight gain during chemotherapy is associated with tumour recurrence and chemotherapy toxicity. We assessed the efficacy of intermittent energy restriction (IER) vs continuous energy restriction (CER) for weight control and toxicity reduction during chemotherapy. Methods One hundred and seventy-two women were randomised to follow IER or CER throughout adjuvant/neoadjuvant chemotherapy. Primary endpoints were weight and body fat change. Secondary endpoints included chemotherapy toxicity, cardiovascular risk markers, and correlative markers of metabolism, inflammation and oxidative stress. Results Primary analyses showed non-significant reductions in weight (-1.1 (-2.4 to +0.2) kg, p = 0.11) and body fat (-1.0 (-2.1 to +0.1) kg, p = 0.086) in IER compared with CER. Predefined secondary analyses adjusted for body water showed significantly greater reductions in weight (-1.4 (-2.5 to -0.2) kg, p = 0.024) and body fat (-1.1 (-2.1 to -0.2) kg, p = 0.046) in IER compared with CER. Incidence of grade 3/4 toxicities were comparable overall (IER 31.0 vs CER 36.5%, p = 0.45) with a trend to fewer grade 3/4 toxicities with IER (18%) vs CER (31%) during cycles 4-6 of primarily taxane therapy (p = 0.063). Conclusions IER is feasible during chemotherapy. The potential efficacy for weight control and reducing toxicity needs to be tested in future larger trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据